|
private:gen1elifesci
|
18860019
|
Apr 21st, 2024 12:00AM
|
GEn1E Lifesciences Inc.
|
648
|
16.00
|
Open
|
|
Apr 21st, 2024 06:12AM
|
Apr 21st, 2024 06:12AM
|
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA).
GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.
With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.
GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
|
Open
|
ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery
|
Open
|
El Camino Real
|
Palo Alto
|
California
|
US
|
|
|
GEn1E Lifesciences
|
|
|
|
private:gen1elifesci
|
18860019
|
Apr 20th, 2024 12:00AM
|
GEn1E Lifesciences Inc.
|
648
|
16.00
|
Open
|
|
Apr 20th, 2024 05:11AM
|
Apr 20th, 2024 08:28PM
|
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA).
GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.
With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.
GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
|
Open
|
ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery
|
Open
|
El Camino Real
|
Palo Alto
|
California
|
US
|
|
|
GEn1E Lifesciences
|
|
|
|
private:gen1elifesci
|
18860019
|
Apr 19th, 2024 12:00AM
|
GEn1E Lifesciences Inc.
|
648
|
16.00
|
Open
|
|
Apr 19th, 2024 07:35AM
|
Apr 19th, 2024 07:35AM
|
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA).
GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.
With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.
GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
|
Open
|
ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery
|
Open
|
El Camino Real
|
Palo Alto
|
California
|
US
|
|
|
GEn1E Lifesciences
|
|
|
|
private:gen1elifesci
|
18860019
|
Apr 18th, 2024 12:00AM
|
GEn1E Lifesciences Inc.
|
648
|
16.00
|
Open
|
|
Apr 18th, 2024 06:16AM
|
Apr 18th, 2024 09:48PM
|
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA).
GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.
With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.
GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
|
Open
|
ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery
|
Open
|
El Camino Real
|
Palo Alto
|
California
|
US
|
|
|
GEn1E Lifesciences
|
|
|
|
private:gen1elifesci
|
18860019
|
Apr 17th, 2024 12:00AM
|
GEn1E Lifesciences Inc.
|
648
|
16.00
|
Open
|
|
Apr 17th, 2024 07:35AM
|
Apr 17th, 2024 06:16PM
|
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA).
GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.
With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.
GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
|
Open
|
ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery
|
Open
|
El Camino Real
|
Palo Alto
|
California
|
US
|
|
|
GEn1E Lifesciences
|
|
|
|
private:gen1elifesci
|
18860019
|
Apr 16th, 2024 12:00AM
|
GEn1E Lifesciences Inc.
|
648
|
16.00
|
Open
|
|
Apr 16th, 2024 05:01AM
|
Apr 16th, 2024 02:34PM
|
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA).
GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.
With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.
GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
|
Open
|
ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery
|
Open
|
El Camino Real
|
Palo Alto
|
California
|
US
|
|
|
GEn1E Lifesciences
|
|
|
|
private:gen1elifesci
|
18860019
|
Apr 15th, 2024 12:00AM
|
GEn1E Lifesciences Inc.
|
648
|
16.00
|
Open
|
|
Apr 15th, 2024 07:55AM
|
Apr 15th, 2024 08:15PM
|
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA).
GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.
With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.
GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
|
Open
|
ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery
|
Open
|
El Camino Real
|
Palo Alto
|
California
|
US
|
|
|
GEn1E Lifesciences
|
|
|
|
private:gen1elifesci
|
18860019
|
Apr 14th, 2024 12:00AM
|
GEn1E Lifesciences Inc.
|
647
|
16.00
|
Open
|
|
Apr 14th, 2024 03:53AM
|
Apr 14th, 2024 03:53AM
|
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA).
GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.
With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.
GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
|
Open
|
ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery
|
Open
|
El Camino Real
|
Palo Alto
|
California
|
US
|
|
|
GEn1E Lifesciences
|
|
|
|
private:gen1elifesci
|
18860019
|
Apr 13th, 2024 12:00AM
|
GEn1E Lifesciences Inc.
|
647
|
16.00
|
Open
|
|
Apr 13th, 2024 02:49AM
|
Apr 13th, 2024 02:57PM
|
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA).
GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.
With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.
GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
|
Open
|
ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery
|
Open
|
El Camino Real
|
Palo Alto
|
California
|
US
|
|
|
GEn1E Lifesciences
|
|
|
|
private:gen1elifesci
|
18860019
|
Apr 12th, 2024 12:00AM
|
GEn1E Lifesciences Inc.
|
647
|
16.00
|
Open
|
|
Apr 12th, 2024 03:00AM
|
Apr 12th, 2024 12:03PM
|
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA).
GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.
With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.
GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
|
Open
|
ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery
|
Open
|
El Camino Real
|
Palo Alto
|
California
|
US
|
|
|
GEn1E Lifesciences
|
|
|